FTC settles with HeartBar marketers
This article was originally published in The Tan Sheet
Executive Summary
Unither Pharma and United Therapeutics will cease making certain ad claims for their L-arginine-containing HeartBar following FTC allegations the claims are unsupported by scientific evidence, according to 1June 12 settlement. Agreement prohibits multiple claims such as "HeartBar decreases leg pain, prevents age-related vascular problems, reduces the risk of cardiovascular disease and reduces or eliminates the need for surgery and medications among patients with" CVD, which appeared on 2Unither's Web site and in print ads, FTC says. United Therapeutics acquired HeartBar when it purchased Cooke Pharma in 2000 (3"The Tan Sheet" Jan. 1, 2001, p. 5)...
You may also be interested in...
United Therapeutics Cooke Pharma Buyout Provides Added Marketing/R&D
United Therapeutics Corporation's acquisition of Cooke Pharma will give the HeartBar manufacturer a boost in marketing and research and development resources.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.